Skip to content

Photodynamic diagnosis by LED endoscopy system

Exploratory study to evaluate efficacy, safety and fluorescent molecule infrastructure of photodynamic diagnosis for upper and lower gastrointestinal tumors using LED endoscopy system

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs061200034
Enrollment
60
Registered
2020-12-07
Start date
2021-03-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alimentary canal tumor

Interventions

Aminolevulinic acid hydrochloride administration, non-approved endoscope system usage

Sponsors

Isomoto Hajime
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) 18 or above years old male or female 2) Patients who undergo endoscopic examination (criteria 1) or treatment (criteria 2) for gastrointestinal tumor Criteria 1: Patients with (Including suspected symptoms) colitic cancer or DALM (dysplasia-associated lesions or mass) related to inflammatory bowel disease Criteria 2: Patients with (Including suspected symptoms) esophageal tumor, gastric tumor, duodenal tumor or colon tumor 3) Patients with ECOG Performance Status 0 or 1 4) Patients with preserved heart, lung, liver and kidney function 5) Patients who received written consent from the study subject. For below the age of 20, patients who have also obtained consent from their legal representatives.

Exclusion criteria

Exclusion criteria: 1) Patients with a history of hypersensitivity to 5-ALA or porphyrin 2) Porphyria patients 3) Patients who need to take medicines or foods known to cause photosensitivity from admission to 14 days postdose. 4) Patients with absolute contraindications to gastrointestinal endoscopy 5) Pregnant women or patients who may be pregnant 6) Patients who cannot ingest 7) Patients who cannot be properly shielded 48 hours postdose 8) Patients who received drug treatment for malignant tumor within 1 month before obtaining consent 9) Patients who received study drug within 3 months before study drug administration

Design outcomes

Primary

MeasureTime frame
Detection rate of alimentary canal tumor by LED photodynamic endoscopic diagnosis with 5-ALA

Secondary

MeasureTime frame
1) Detection sensitivity, specificity, positive rate and negative rate of alimentary canal tumor in LED photodynamic endoscopic diagnosis with 5-ALA 2) Advesed event 3) PpIX specific fluorescence spectrum measured by a spectroscope in LED photodynamic endoscopic diagnosis with 5-ALA for alimentary canal tumor 4) Correlation between LED photodynamic endoscopic diagnosis with 5-ALA for alimentary canal tumor and PpIX intrinsic fluorescence spectrum measured by spectroscope, clinicopathologic features, magnifying endoscope findings 5) Correlation between activity or expression of related molecules and fluorescence in LED photodynamic endoscopic diagnosis with 5-ALA for alimentary canal tumor 6) Detectability of multiple synchronous lesions by LED photodynamic endoscopic diagnosis with 5-ALA

Contacts

Public ContactYusuke Endo

Tottori University Hospital

y-endo@tottori-u.ac.jp+81-859-38-6946

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026